Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a new issue of shares with preferential rights for the company's shareholders. Through the new issue, the number of shares has increased by 478,147 A-shares and 53,251,966 B-shares and the number of votes has increased by 54,686,407.

The total number of shares amounts to 90,930,755, of which 971,024 are A shares and 89,959,731 are B shares. The total number of votes after the conversions amounts to 92,872,803. The share capital has increased by SEK 16,132,677.74 and now amounts to SEK 27,302,316.80.

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on July 31, 2019. 

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.